EQS-News: Semperit strengthened for further growth after transformation year – earnings 2023 still burdened by sold medical business
Earnings after tax from continued operations were positive at EUR 24.9 million, while the loss from the medical business, which has been sold, had a significant negative impact as expected.
- Earnings after tax from continued operations were positive at EUR 24.9 million, while the loss from the medical business, which has been sold, had a significant negative impact as expected.
- Earnings development 2023 in detail:
The continued operations of the Semperit Group recorded revenue of EUR 721.1 million (–7.5%) in the 2023 financial year. - Also considering the proceeds from the sale of Examination Operations (medical business), results in EUR 111.5 million (previous year: EUR –2.8 million).
- Overview of the main financial figures of the financial year 2023:
Key figures of the Semperit Group, in EUR million